Pasi Antero Janne
Dana-Farber Cancer Institute
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Lung Cancer Treatments and Mutations
Strong evidence · 4 supporting papers · latest 2026
PARP inhibition in cancer therapy
Solid evidence · 1 supporting paper · latest 2026
HER2/EGFR in Cancer Research
Solid evidence · 2 supporting papers · latest 2026
Protein Kinase Regulation and GTPase Signaling
Solid evidence · 1 supporting paper · latest 2026
Endoplasmic Reticulum Stress and Disease
Supporting evidence · 1 supporting paper · latest 2026
Peptidase Inhibition and Analysis
Supporting evidence · 1 supporting paper · latest 2026
Heat shock proteins research
Supporting evidence · 1 supporting paper · latest 2026
Genetic Associations and Epidemiology
Supporting evidence · 1 supporting paper · latest 2026
Publications (7)
Long-term safety of first-line osimertinib plus platinum–pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2
2026DOIPMID 42728193
Germline EGFR T790M mutation and lung cancer risk
2026DOIPMID 42752144
PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer
2026DOIPMID 42628527
DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC
2026DOIPMID 42682104
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
2026DOIPMID 42612796
Supplementary Tables1 from Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
2026DOI
Supplementary Figures1 from Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Dana-Farber Cancer Institute
Source: OpenAlex · retrieved 2026-09-29